In8Bio INAB
NASDAQ INAB
$1.04 +0.05 (+4.55%)
As of: Oct 23, 2026 · 3:59 PM EDT

In8Bio (INAB) Capital Expenditures (2021 - 2026)

Updated

In8Bio (INAB) recorded Capital Expenditures of $233,000 in Q2 2026.

Analysis

In8Bio (INAB) Capital Expenditures (2021 - 2026) Analysis & Trends

On a TTM basis, In8Bio's Capital Expenditures came in at $242,000 as of Jun 30, 2026, up 633.3% year-over-year; for FY2024, it came in at $104,000, down 74.3% from FY2023.

  • Across earlier years, Capital Expenditures came in at $405,000 in FY2023 (-89.0%) and $3.69 million in FY2022.
  • The Q2 2026 figure is the highest quarterly Capital Expenditures since Q1 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn 2.93 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn 1.36 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn 322.00 Mn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn 893.00 Mn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn 321.00 Mn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 1.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn 513.00 Mn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 140.00 Mn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn 533.00 Mn
10 In8Bio 20.25 Mn -58.10 Mn - 233,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 233,000.00
Mar 31, 2026 9,000.00
Dec 31, 2024 33,000.00
Jun 30, 2024 83,000.00
Mar 31, 2024 71,000.00
Dec 31, 2023 72,000.00
Sep 30, 2023 77,000.00
Jun 30, 2023 22,000.00
Mar 31, 2023 429,000.00
Dec 31, 2022 1.26 Mn
Sep 30, 2022 1.76 Mn
Jun 30, 2022 425,000.00
Mar 31, 2022 253,000.00
Dec 31, 2021 156,000.00
API Access

In8Bio Capital Expenditures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-expenditures&ticker=INAB&period=max&api_key=YOUR_API_KEY